EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to increase bedaquiline activity

Adam J Fountain, Natalie J E Waller, Chen-Yi Cheung, William Jowsey, Michael T Chrisp, Mark Troll, Paul H Edelstein iD, Gregory M Cook iD, Matthew B McNeil iD, Lalita Ramakrishnan iD

Proceedings of the National Academy of Sciences · 22.04.2025 · 122 (16)

DOI: 10.1073/pnas.2426827122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 17.04.2025. Verfasst von Adam J Fountain und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, United Kingdom. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Diarylquinolines, Verapamil, Antitubercular Agents. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust (WT), Maurice Wilkins Centre for Molecular Biodiscovery and the Marsden Fund (Royal Society of New Zealand), NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bedaquiline is the cornerstone of a new regimen for the treatment of drug-resistant tuberculosis. However, its clinical use is threatened by the emergence of bedaquiline-resistant strains of Mycobacterium tuberculosis . Bedaquiline targets mycobacterial ATP synthase but the predominant route to clinical bedaquiline resistance is via upregulation of the MmpS5L5 efflux pump due to mutations that inactivate the transcriptional repressor Rv0678 . Here, we show that the MmpS5L5 efflux pump reduces susceptibility to bedaquiline as well as its new, more potent derivative TBAJ-876 and other antimicrobial substrates, including clofazimine and the DprE1 inhibitors PBTZ-169 and OPC-167832. Furthermore, the increased resistance of Rv0678 mutants stems entirely from increased MmpS5L5 expression. These results highlight the potential of a pharmacological MmpS5L5 inhibitor to increase drug efficacy. Verapamil, primarily used as a calcium channel inhibitor, is known to inhibit diverse efflux pumps and to potentiate bedaquiline and clofazimine activity in M. tuberculosis . Here, we show that verapamil potentiates the activity of multiple diverse MmpS5L5 substrates. Using biochemical approaches, we demonstrate that verapamil does not exert this effect by acting as a disruptor of the protonmotive force used to power MmpS5L5, as previously proposed, suggesting that verapamil inhibits the function of the MmpS5L5 pump. Finally, norverapamil, the major verapamil metabolite, which has greatly reduced calcium channel activity, has equal potency in reducing resistance to MmpS5L5 substrates. Our findings highlight verapamil’s potential for enhancing bedaquiline TB treatment, for preventing acquired resistance to bedaquiline and other MmpS5L5 substrates, while also providing the impetus to identify additional MmpS5L5 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisDiarylquinolinesVerapamilAntitubercular AgentsBacterial ProteinsMembrane Transport ProteinsMicrobial Sensitivity TestsDrug Resistance, Bacterial

Stichwörter der Autor:innen

MmpS5L5 drug efflux pumpMycobacterium tuberculosisTBAJ-587 and TBAJ-876bedaquilineverapamil and norverapamil

Substanzen

bedaquilineDiarylquinolinesVerapamilAntitubercular AgentsBacterial ProteinsMembrane Transport Proteins

Autor:innen und Institutionen

  • Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, United Kingdom.
  • Molecular Immunity Unit, Cambridge Institute of Therapeutic Immunology and Infectious Diseases, Department of Medicine, University of Cambridge, Cambridge CB2 0AW, United Kingdom.
  • Department of Microbiology and Immunology, University of Otago, Dunedin 9053, New Zealand.

ORCID-Profile: Paul H Edelstein, Gregory M Cook, Matthew B McNeil, Lalita Ramakrishnan

Förderung

  • Wellcome Trust (WT)
  • Maurice Wilkins Centre for Molecular Biodiscovery and the Marsden Fund (Royal Society of New Zealand)
  • NIAID NIH HHS
  • Foundation for the NIH

Zitieren

APA

Fountain, A. J., Waller, N. J. E., Cheung, C. Y., Jowsey, W., Chrisp, M. T., Troll, M., Edelstein, P. H., Cook, G. M., McNeil, M. B., & Ramakrishnan, L. (2025). Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to increase bedaquiline activity. Proceedings of the National Academy of Sciences, 122(16). https://doi.org/10.1073/pnas.2426827122

Vancouver

Fountain AJ, Waller NJE, Cheung CY, Jowsey W, Chrisp MT, Troll M, et al. Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to increase bedaquiline activity. Proceedings of the National Academy of Sciences. 2025;122(16). doi:10.1073/pnas.2426827122

BibTeX
@article{Fountain2025,
  author = {Fountain, Adam J and Waller, Natalie J E and Cheung, Chen-Yi and Jowsey, William and Chrisp, Michael T and Troll, Mark and Edelstein, Paul H and Cook, Gregory M and McNeil, Matthew B and Ramakrishnan, Lalita},
  title = {Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to increase bedaquiline activity},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  volume = {122},
  number = {16},
  doi = {10.1073/pnas.2426827122}
}
Kostenlos starten →